Par Drugs and Chemicals (NSEI:PAR) - Aandelenkoers, Nieuws & Analyse

De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!

PAR Overzicht aandelen

Par Drugs and Chemicals Limited ontwikkelt, produceert en verkoopt actieve farmaceutische ingrediënten (API's) en fijnchemicaliën in India.

Over het bedrijf

PAR fundamentele analyse
Sneeuwvlok Score
Waardering	3/6
Toekomstige groei	0/6
Prestaties in het verleden	5/6
Financiële gezondheid	6/6
Dividenden	0/6

Beloningen

Trading at 5.3% below our estimate of its fair value

Earnings grew by 26.6% over the past year

Risicoanalyse

Does not have a meaningful market cap (₹3B)

Significant insider selling over the past 3 months

Par Drugs and Chemicals Limited Concurrenten

Natural Capsules

BSE:524654

₹3.2b

Panchsheel Organics

BSE:531726

₹2.8b

Zenith Drugs

NSEI:ZENITHDRUG

₹2.2b

Alpa Laboratories

NSEI:ALPA

₹2.8b

Prijsgeschiedenis en prestaties

Overzicht van alle hoogtepunten, veranderingen en prijsdalingen voor Par Drugs and Chemicals
Historische aandelenkoersen
Huidige aandelenkoers	₹232.06
52 Week Hoogtepunt	₹325.00
52 Week Laag	₹190.15
Bèta	0.26
11 maand verandering	-8.35%
3 maanden verandering	-4.20%
1 Jaar Verandering	12.57%
33 jaar verandering	-4.70%
5 jaar verandering	877.09%
Verandering sinds IPO	819.96%

Recent nieuws en updates

Improved Earnings Required Before Par Drugs and Chemicals Limited (NSE:PAR) Stock's 29% Jump Looks Justified

Apr 16

Recent updates

Improved Earnings Required Before Par Drugs and Chemicals Limited (NSE:PAR) Stock's 29% Jump Looks Justified

Apr 16

Here's Why We Think Par Drugs and Chemicals (NSE:PAR) Might Deserve Your Attention Today

Apr 05

Do Par Drugs and Chemicals' (NSE:PAR) Earnings Warrant Your Attention?

Nov 03

If EPS Growth Is Important To You, Par Drugs and Chemicals (NSE:PAR) Presents An Opportunity

May 19

Does Par Drugs and Chemicals (NSE:PAR) Deserve A Spot On Your Watchlist?

Mar 17

Do Par Drugs and Chemicals's (NSE:PAR) Earnings Warrant Your Attention?

Oct 22

Investors Shouldn't Be Too Comfortable With Par Drugs and Chemicals' (NSE:PAR) Robust Earnings

Aug 11

Here's Why We Think Par Drugs and Chemicals (NSE:PAR) Is Well Worth Watching

Jul 14

Is Par Drugs and Chemicals Limited (NSE:PAR) An Attractive Dividend Stock?

Mar 31

Are Strong Financial Prospects The Force That Is Driving The Momentum In Par Drugs and Chemicals Limited's NSE:PAR) Stock?

Mar 05

Chairman of the Board & MD Falgun Savani Just Bought A Handful Of Shares In Par Drugs and Chemicals Limited (NSE:PAR)

Feb 06

Here's Why I Think Par Drugs and Chemicals (NSE:PAR) Might Deserve Your Attention Today

Jan 10

How Does Par Drugs and Chemicals Limited (NSE:PAR) Fare As A Dividend Stock?

Dec 13

Rendement voor aandeelhouders

	PAR	IN Pharmaceuticals	IN Markt
7D	-1.8%	0.2%	-0.3%
1Y	12.6%	59.4%	44.6%

Rendement versus industrie: PAR underperformed the Indian Pharmaceuticals industry which returned 58.2% over the past year.

Rendement versus markt: PAR underperformed the Indian Market which returned 44.2% over the past year.

Prijsvolatiliteit

Is PAR's price volatile compared to industry and market?
PAR volatility
PAR Average Weekly Movement	5.0%
Pharmaceuticals Industry Average Movement	6.2%
Market Average Movement	6.2%
10% most volatile stocks in IN Market	9.3%
10% least volatile stocks in IN Market	3.9%

Stabiele aandelenkoers: PAR has not had significant price volatility in the past 3 months.

Volatiliteit in de loop van de tijd: PAR's weekly volatility (5%) has been stable over the past year.

Over het bedrijf

Opgericht	Werknemers	CEO	Website
1982	122	Jignesh Savani	www.pardrugs.com

Par Drugs and Chemicals Limited ontwikkelt, produceert en verkoopt actieve farmaceutische ingrediënten (API's) en fijnchemicaliën in India. Het bedrijf levert API-producten, waaronder magnesiumhydroxide, magnesiumoxide USP, sucralfaat, almagaat BP, gedroogde aluminiumhydroxidegel, licht magnesiumcarbonaat, magaldraat, magnesiumtrisilicaat, colloïdaal siliciumdioxide, aluminiummagnesiumsilicaat, magnesiumaluminometasilicaat, magnesiumaluminosilicaat-USP, magnesiumoxide licht, magnesiumoxide zwaar, magnesiumaluminiumhydraat, hydrotalciet en synthetisch aluminiumsilicaat. Het biedt fijnchemicaliën, zoals geprecipiteerd silica, natriumaluminiumsilicaat, amorf aluminiumhydroxide, PARSIL-HT, PAR ADD OP, MagSil OF, FlowSil, aluminiumhydroxide-magnesiumcarbonaat-gedroogde gel, magnesiumaluminiumsilicaat gehydrateerd (farma) en magnesiumaluminiumsilicaat gehydrateerd (agro).

Par Drugs and Chemicals Limited Samenvatting

Hoe verhouden de winst en inkomsten van Par Drugs and Chemicals zich tot de beurswaarde?
PAR fundamentele statistieken
Marktkapitalisatie	₹2.86b
Inkomsten(TTM)	₹145.67m
Inkomsten(TTM)	₹953.11m

19.6x

Koers/Winstverhouding

3.0x

P/S-verhouding

Is PAR overgewaardeerd?

Zie Reële waarde en waarderingsanalyse

Inkomsten en omzet

Belangrijkste winstgevendheidsstatistieken uit het laatste winstverslag (TTM)
PAR resultatenrekening (TTM)
Inkomsten	₹953.11m
Kosten van inkomsten	₹316.07m
Brutowinst	₹637.04m
Overige uitgaven	₹491.38m
Inkomsten	₹145.67m

Laatst gerapporteerde inkomsten

Jun 30, 2024

Volgende inkomensdatum

n.v.t.

Winst per aandeel (EPS)	11.84
Brutomarge	66.84%
Nettowinstmarge	15.28%
Schuld/Eigen Vermogen Verhouding	0%

Hoe presteerde PAR op de lange termijn?

Bekijk historische prestaties en vergelijking

PAR Overzicht aandelen

Beloningen

Risicoanalyse

Par Drugs and Chemicals Limited Concurrenten

BSE:524654

₹3.2b

BSE:531726

₹2.8b

NSEI:ZENITHDRUG

₹2.2b

NSEI:ALPA

₹2.8b

Prijsgeschiedenis en prestaties

Recent nieuws en updates

CEO & Executive Director recently sold ₹23m worth of stock

Par Drugs and Chemicals Limited, Annual General Meeting, Sep 21, 2024

First quarter 2025 earnings released: EPS: ₹2.06 (vs ₹2.01 in 1Q 2024)

Full year 2024 earnings released: EPS: ₹11.78 (vs ₹9.21 in FY 2023)

Now 23% overvalued after recent price rise

Improved Earnings Required Before Par Drugs and Chemicals Limited (NSE:PAR) Stock's 29% Jump Looks Justified

Recent updates

CEO & Executive Director recently sold ₹23m worth of stock

Par Drugs and Chemicals Limited, Annual General Meeting, Sep 21, 2024

First quarter 2025 earnings released: EPS: ₹2.06 (vs ₹2.01 in 1Q 2024)

Full year 2024 earnings released: EPS: ₹11.78 (vs ₹9.21 in FY 2023)

Now 23% overvalued after recent price rise

Improved Earnings Required Before Par Drugs and Chemicals Limited (NSE:PAR) Stock's 29% Jump Looks Justified

Here's Why We Think Par Drugs and Chemicals (NSE:PAR) Might Deserve Your Attention Today

Third quarter 2024 earnings released: EPS: ₹2.78 (vs ₹1.52 in 3Q 2023)

Do Par Drugs and Chemicals' (NSE:PAR) Earnings Warrant Your Attention?

Second quarter 2024 earnings released: EPS: ₹3.97 (vs ₹3.03 in 2Q 2023)

Insufficient new directors

Investor sentiment improves as stock rises 15%

Par Drugs and Chemicals Limited, Annual General Meeting, Sep 16, 2023

First quarter 2024 earnings released: EPS: ₹2.01 (vs ₹1.86 in 1Q 2023)

Investor sentiment improves as stock rises 23%

If EPS Growth Is Important To You, Par Drugs and Chemicals (NSE:PAR) Presents An Opportunity

Full year 2023 earnings released: EPS: ₹9.21 (vs ₹7.49 in FY 2022)

Third quarter 2023 earnings released: EPS: ₹1.52 (vs ₹1.72 in 3Q 2022)

Second quarter 2023 earnings released: EPS: ₹3.03 (vs ₹1.80 in 2Q 2022)

Investor sentiment improved over the past week

First quarter 2023 earnings released: EPS: ₹1.86 (vs ₹1.90 in 1Q 2022)

Par Drugs and Chemicals Limited, Annual General Meeting, Sep 10, 2022

Investor sentiment improved over the past week

Full year 2022 earnings released: EPS: ₹7.49 (vs ₹9.44 in FY 2021)

Does Par Drugs and Chemicals (NSE:PAR) Deserve A Spot On Your Watchlist?

Non Executive Director recently bought ₹304k worth of stock

CEO & Executive Director recently bought ₹313k worth of stock

Investor sentiment deteriorated over the past week

Third quarter 2022 earnings: Revenues and EPS in line with analyst expectations

High number of new directors

CEO & Executive Director recently bought ₹199k worth of stock

CEO & Executive Director recently bought ₹189k worth of stock

Investor sentiment deteriorated over the past week

Upcoming dividend of ₹1.25 per share

Second quarter 2022 earnings released: EPS ₹1.80 (vs ₹2.08 in 2Q 2021)

Investor sentiment deteriorated over the past week

Do Par Drugs and Chemicals's (NSE:PAR) Earnings Warrant Your Attention?

Investor sentiment improved over the past week

Investors Shouldn't Be Too Comfortable With Par Drugs and Chemicals' (NSE:PAR) Robust Earnings

Full year 2021 earnings released: EPS ₹9.44 (vs ₹3.87 in FY 2020)

Investor sentiment improved over the past week

Here's Why We Think Par Drugs and Chemicals (NSE:PAR) Is Well Worth Watching

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Is Par Drugs and Chemicals Limited (NSE:PAR) An Attractive Dividend Stock?

Investor sentiment improved over the past week

Are Strong Financial Prospects The Force That Is Driving The Momentum In Par Drugs and Chemicals Limited's NSE:PAR) Stock?

Investor sentiment improved over the past week

New 90-day high: ₹73.40

CEO & Executive Director recently bought ₹391k worth of stock

Chairman of the Board & MD Falgun Savani Just Bought A Handful Of Shares In Par Drugs and Chemicals Limited (NSE:PAR)

Chairman of the Board & MD recently bought ₹263k worth of stock

Here's Why I Think Par Drugs and Chemicals (NSE:PAR) Might Deserve Your Attention Today

Investor sentiment improved over the past week

How Does Par Drugs and Chemicals Limited (NSE:PAR) Fare As A Dividend Stock?

Market bids up stock over the past week

New 90-day high: ₹55.90

New 90-day high: ₹51.00